Ingevity's Bold Moves: A Game-Changer for Stockholders!

Ladies and gentlemen, buckle up! Ingevity Corporation (NYSE: NGVT) has just dropped a bombshell with its definitive proxy statement and a letter to stockholders that's got me screaming, "BUY NOW!" This isn't just a company; it's a rocket ship ready to blast off into the stratosphere of stock market success. Let's dive in and see why this is a no-brainer for your portfolio!



First things first, Ingevity's Board and management team have been busy bees, making some serious transformational changes to tackle external market challenges. They've closed facilities, diversified raw material streams, and exited lower margin, cyclical end markets. Why? Because they're playing the long game, folks! These moves are all about setting the stage for sustained growth and profitability.

Now, let's talk numbers. In 2024, Ingevity delivered revenues of $1.4+ billion, the third highest year in its history. Adjusted EBITDA was $362+ million at a 26% margin, beating consensus by ~3%. Cost savings of $84 million exceeded expectations, and free cash flow of $51 million was way above prior guidance. This is not just growth; this is EXPLOSIVE growth!

But wait, there's more! Ingevity's Board has appointed David H. Li as the next President and CEO, effective April 7, 2025. This is a strategic move to ensure strong oversight and continued execution of the company's initiatives. And if that wasn't enough, they've also appointed Michael N. Shukov as senior vice president and president of Advanced Polymer Technologies. This guy brings over 25 years of specialty chemicals experience and a track record of transforming business profitability. Talk about a dream team!

Now, let's address the elephant in the room. Vision One, a hedge fund, is trying to stir up trouble with a proxy fight. But Ingevity is having none of it. They've made meaningful efforts to reach a constructive resolution, but Vision One has rejected these efforts. The company is urging stockholders to vote "FOR" ONLY Ingevity’s nine highly qualified director nominees on the WHITE proxy card. This is a clear message to Vision One: "Drop the proxy fight and let the professionals do their job!"



So, what does this all mean for you, the investor? It means that Ingevity is poised for continued momentum in 2025, with projected 10-14% adjusted EBITDA growth, free cash flow that is approximately 4-5x the 2024 level, additional cost savings of $10-25 million, and a reduction in net debt. This is a company that's not just surviving; it's THRIVING!

In conclusion, Ingevity's bold moves are a game-changer for stockholders. The company's transformational changes, strong financial performance, and strategic leadership appointments make it a no-brainer for your portfolio. So, don't miss out on this opportunity to be part of Ingevity's success story. Vote "FOR" Ingevity’s directors and get ready to ride the rocket ship to the moon!